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Background: Nonbullous pemphigoid is an under-recognized phenotype of the 
autoimmune bullous disease pemphigoid, characterized by the absence of blisters. 
Several disease aspects have not been studied previously.  
Objective: To describe the characteristics of nonbullous pemphigoid. 
Methods: A retrospective chart review study. The diagnosis of pemphigoid was 
based on meeting two of the following three criteria; 1) pruritus, 2) positive direct 
immunofluorescence microscopy (DIF), 3) positive indirect immunofluorescence 
microscopy (IIF) on salt-split skin. 
Results: Sixty-nine patients were included. The mean delay in diagnosis was 29 
months. Skin examination most often showed pruritic papules/nodules (37%) or 
pruritus without primary skin lesions (22%). Histopathological findings were mainly 
nonspecific. DIF and IIF were positive in 60% and 69%. During follow-up blisters 
formed in 17%, which was associated with a positive IIF (p=0.014), and positive 
BP180 immunoblot result (p=0.032). The Kaplan-Meier estimates of 1-, 2- and 3-
year mortality were 14%, 34%, and 46%, with an 8.6 fold increased all-cause 
mortality risk.  
Limitations: The retrospective study design. 
Conclusion: Nonbullous pemphigoid presented with heterogeneous pruritic skin 
lesions, resulting in delayed diagnosis. DIF and IIF are essential to diagnose 
nonbullous pemphigoid, in contrast to histopathology, mainly showing nonspecific 
findings. During follow-up, an increased all-cause mortality risk was observed. 
 




  Nonbullous pemphigoid is an under-recognized variant of pemphigoid with long 
diagnostic delays. Patients present with symptoms of pruritus, with or without 
skin lesions. 
 Clinicians should realize that histopathology is not useful for diagnosing 
nonbullous pemphigoid; direct- and indirect immunofluorescence are required. 
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LIST OF ABBREVIATIONS 
BP  bullous pemphigoid 
BMZ  basement membrane zone 
CR  complete remission 
DC  disease control 
DIF   direct immunofluorescence microscopy 
ELISA enzyme linked immunosorbent assay 
HR  hazard ratio 
IIF   indirect immunofluorescence microscopy 
MO  monkey oesophagus 
NC16A noncollagenous 16A domain of BP180 
PR  partial remission 
SMR  standardized mortality ratio 
SSS  salt-split skin 




Pemphigoid is an autoantibody mediated skin disease mainly affecting elderly 
patients.1 Autoantibodies target structural proteins BP180 and BP230 located in the 
basement membrane zone (BMZ), inducing an eosinophilic inflammatory response 
in the skin.2 Interestingly, the immunological disease mechanism in pemphigoid can 
lead to two distinct clinical phenotypes, termed bullous and nonbullous pemphigoid. 
 Bullous pemphigoid (BP) classically presents with severe pruritus and tense 
blisters on urticarial plaques.1 There is a high co-occurrence of psychiatric- and 
neurodegenerative diseases, and patients have an increased mortality risk 
compared to the age-matched general population.3–6 One in five patients lack typical 
blisters, termed nonbullous pemphigoid.7 Patients present with pruritus and a wide 
spectrum of skin manifestations that may resemble other pruritic skin diseases.8–12 
Consequently, patients often have a long diagnostic delay.13,14 Urticarial plaques 
and papules/nodules are reported most frequently.8–12 Blister development during 
disease course is reported in ten percent.8  
 The diagnosis of nonbullous pemphigoid is based on the detection of either skin-
bound IgG or complement C3 in a linear deposition along the BMZ by direct 
immunofluorescence microscopy (DIF), and/or circulating antibodies by indirect 
immunofluorescence microscopy (IIIF) on salt-split skin (SSS).7 Histopathology is 
often nonspecific.8   
 To date, little is known about the management and prognosis of nonbullous 
pemphigoid. Treatment recommendations of BP are often followed, recommending 
whole body application of superpotent topical corticosteroids as initial therapy.15 The 
aim of this study was to describe the clinical and diagnostic findings, treatment 
responses, and follow-up of patients with nonbullous pemphigoid, to support early 
recognition and improve patient care. 
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MATERIALS AND METHODS 
Selection of cases and data collection  
This retrospective study included patients diagnosed with nonbullous pemphigoid 
between 2002-2017 at the dermatology department of the University Medical Center 
Groningen, the Netherlands. Inclusion criteria were based on recently established 
diagnostic criteria by Meijer et al. with two positive out of the following three criteria: 
1) pruritus, 2) linear IgG and/or C3 depositions along the BMZ by DIF, 3) positive 
staining of IgG on the epidermal side of SSS substrate by IIF.7 Exclusion criteria 
were blisters or vesicles prior to diagnosis, or at initial presentation objectified by a 
physician. Cases were excluded if blisters occurred within two months after the 
onset of pruritus, and considered prodromal BP.  
 Clinical characteristics were assessed by reviewing patient charts. Data was 
collected anonymously in electronic case report forms using Open Clinica software. 
The following variables were collected: age, date of first symptoms and diagnosis, 
clinical presentation, skin manifestations, diagnostic findings, treatment response, 
side effects, blister development and death during follow-up. The study was 
approved by the Institutional Review Board at our local ethics committee. 
 
Laboratory tests for pemphigoid 
Laboratory techniques DIF, IIF on SSS and monkey oesophagus (MO), and 
immunoblot were performed at our Immuno-dermatology Laboratory as reported 
previously.7 Autoantibodies against the noncollagenous 16A domain of BP180 
(NC16A) and BP230 were detected with commercially available enzyme linked 
immunosorbent assays (ELISA) according to the manufacturer’s protocol (MBL 
Japan, cut-off index ≥ 9 u/mL).  
 
Treatment response and safety 
Treatment response was assessed by using outcome measurements defined by 
international consensus, consisting of disease control (DC), partial remission (PR) 
on minimal/off therapy, complete remission (CR) on minimal/off therapy, and 
relapse.16 We deviated from the consensus definition by allowing a dose of 7.5 mg 
methotrexate per week to count for minimal therapy. Reported side effects were 
registered. Uncertainties during retrospective assessment were resolved through 
discussion with the study team.  
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Statistical analysis  
Correlations between bivariate outcomes were analyzed with the Pearson Chi-
Square test, or Fisher’s exact test when appropriate. Comparisons of means for 
non-normally distributed data were done with the Mann-Whitney U test. Estimated 
cumulative survival after 1-, 2-, and 3-year follow-up was assessed by Kaplan-Meier 
analysis. Univariate cox regression was performed to investigate the effect of 
selected variables on the 3-year survival. Age-adjusted standardized mortality ratios 
(SMR) were calculated by comparing the objectified 1-year all-cause mortality rates 
in nonbullous pemphigoid with the expected 1-year all-cause mortality rates per age 
group, using mortality data of the Dutch population over the year 2017, provided by 
Statistics Netherlands (CBS, www.cbs.nl). The 95% confidence interval for SMR 
was calculated using Poisson distribution.17 A p-value <0.05 was defined as 
statistical significance. Statistical analyses were performed using IBM SPSS 
statistics version 23. 




Patient characteristics and clinical findings 
Patients’ characteristics are shown in table 1. Patients were relatively old (mean 
76.1 years), and had several comorbidities, such as hypertension (34%), diabetes 
mellitus (24%), atrial fibrillation (13%), and stroke (12%). ACE inhibitors and loop 
diuretics were used in 26% and 20%. Six individual patients reported a time relation 
with onset of symptoms and the use of acenocoumarol, simvastatin, candesartan, 
metoprolol, perindopril and acitretin.  
 Observed skin lesions are displayed in figure 1. Fifteen patients (22%) presented 
with pruritus on primary, nondiseased, noninflamed skin, and showed a significantly 
longer delay in diagnosis compared to patients with primary skin lesions (49.9 vs. 
22.6 months; p=0.018).  
 The average duration of follow-up was 22 months, but varied per patient (0-218 
months). Factors influencing the follow-up duration include death during follow-up, 
response to therapy, and transfer of care of elderly patients with physical limitations 
or long travel distance. Follow-up was longer in patients with systemic treatment.  
 
Diagnostic findings     
Diagnostic findings are summarized in table 2. Histopathology most often showed a 
dermal perivascular infiltrate (98%) with eosinophils (69%), and a subepidermal split 
in only one case. Pathologists most frequently reported nonspecific findings (n=21; 
39%), or findings compatible with cutaneous drug reactions (n=18; 33%), eczema 
(n=12; 22%), urticaria (n=6; 11%), chronic scratching (n=5; 9%), insect bites (n=3; 
6%), or a psoriasiform dermatitis (n=3; 6%).   
 DIF results were positive in 41 of 69 cases (60%), of which 20 cases (29%) had a 
positive IIF on SSS result, and 21 cases (31%) a negative result. In ten of these 21 
cases circulating antibodies against BP180 or BP230 were demonstrated by 
immunoblot or ELISA.  
 In 27 of 69 cases (40%) DIF was negative and the diagnosis based on a positive 
IIF on SSS and compatible pruritic symptoms. Additional positive results by IIF on 
MO, ELISA and immunoblot were found in 26 (96%), 21 (78%) and 17 (63%) cases. 
In one case DIF was not performed, and the diagnosis based on IIF on SSS 
positivity. 
 Immunoblot and ELISA showed that autoantibodies were predominantly directed 
against BP230. BP230 reactivity correlated with negative DIF (p=0.019). 
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Conversely, BP180 reactivity correlated with positive DIF (p=0.048). In cases with 
only BP230 reactivity and no BP180 autoantibodies, a stronger association was 
seen (p=0.001). In 16 cases ELISA titers of IgG against NC16A and BP230 were 
repeated during follow-up, and changes corresponded to clinical symptoms in 
seven, and did not corresponded in nine cases.  
 
Treatment response 
Treatment strategy could vary for individual patients, due to ineffectiveness of 
prescribed topical or systemic therapies prior to diagnosis, or individual patient 
characteristics and comorbidities. Treatment response to initial and second 
prescribed therapies are displayed in table 3. Topical corticosteroids were often 
prescribed awaiting diagnostic test results. Twenty-two patients reported side effects 
during the complete follow-up period. Side effects were experienced by 47% of the 
patients treated with methotrexate (n=32), and treatment needed to be discontinued 




Twelve of 69 cases (17%) developed blisters during follow-up, after a mean disease 
duration of 41.4 months (SD 65.9; R 5-242). Four patients were in remission off 
therapy at the time blisters formed, and six patients in remission on minimal 
systemic therapy. Two patients developed blisters during initially prescribed whole 
body application of superpotent topical corticosteroids. The mean follow-up time of 
cases with blister formation was significantly longer (41.4 months (SD 58.2; R 2-
218)) compared to patients without blister formation (17.7 months (SD 31.7; R 0-
172; p=0.008)).  
  Blister development during follow-up was associated with positive IIF on MO/SSS 
(p=0.014), and positive BP180 immunoblot (p=0.032). Immunoserology tests and 
DIF were repeated in three of 12 cases with blister formation. Increased 
autoantibody titers against both NC16A and BP230 were detected by ELISA in two 
of three cases. DIF was already positive at diagnosis in two cases; in the third case 
DIF turned out positive after blisters occurred. Nevertheless, the alteration from 
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Twenty-five patients (36%) died during follow-up, after mean disease duration of 
51.2 months (SD40.6; R16-153). The mean time between diagnosis and death was 
24.1 months (SD26.3; R0-127). Causes of death were lung cancer (n=1), sepsis 
after a surgical procedure (n=2), heart failure (n=2), and most often unknown 
(n=20). Ten patients were lost to follow-up within the 1-year follow-up period, and 
four additional patients within the 3-year follow-up period, mainly due to referral to a 
peripheral hospital after the diagnosis was made. The Kaplan-Meier estimates of 1-, 
2-, and 3-year all-cause mortality in nonbullous pemphigoid were 14%, 34%, and 
46%. Univariate Cox Regression analysis showed a significant effect of age on the 
3-year survival (HR 1.04; p=0.028). No other factors significantly influenced the 3-
year mortality risk in our population. The SMR per age group is displayed in table 4, 
showing an 8.6-fold increased all-cause mortality risk in the overall nonbullous 
pemphigoid population.    




Patients with nonbullous pemphigoid endured symptoms for an average duration of 
29 months before the correct diagnosis was made. Our study confirmed that 
histopathological findings in nonbullous pemphigoid are nonspecific, and DIF and IIF 
should be performed to establish the diagnosis of nonbullous pemphigoid. 
Methotrexate was most successful in achieving remission, though side effects were 
reported by almost half of the patients. Of importance, an increased all-cause 
mortality risk was demonstrated, indicating that a lack of blisters is not equivalent to 
a mild prognosis. 
 We found a considerable longer diagnostic delay in nonbullous pemphigoid, 
compared to BP (29 vs. 6 months).18 Dermatologists should perform DIF and IIF on 
SSS even in the absence of blisters when considering pemphigoid. The low-hanging 
fruit of unrecognized nonbullous pemphigoid can easily be harvested by the 
aforementioned tests in elderly patients with refractory chronic pruritus. The 
diagnostic value of routine histopathology for the diagnosis of pemphigoid is poor. 
Eosinophilic spongiosis and a subepidermal split are considered histopathological 
hallmarks of BP.1 In fact, these findings are less typical than implied, as a recent 
study could only confirm eosinophilic spongiosis in 50% and a subepidermal split in 
54% of BP cases.19 We observed that only in 6% of the nonbullous pemphigoid 
cases eosinophils infiltrated the epidermis. Furthermore, eosinophils were found in a 
perivascular infiltrate (69%), and in the peripheral blood (45%). Eosinophils are 
hypothesized to mediate blister formation through secretion of toxic granule 
proteins.20,21 In nonbullous pemphigoid eosinophils may be activated and attracted 
towards the skin, but may be unable to infiltrate the epidermis and induce blistering.  
 A notable observation is the predominant reactivity against BP230 in nonbullous 
pemphigoid, correlating with a negative DIF result, also described by previous 
studies.8,22,23 It is suggested that the intracellular localization of BP230 might hinder 
binding of autoantibodies in skin, resulting in negative staining by DIF.24 In 
contradiction, we found ten nonbullous pemphigoid cases with positive DIF, and only 
circulating BP230 autoantibodies. Meijer et al. previously showed that 
autoantibodies against BP180 NC16A are more often present in BP compared to 
nonbullous pemphigoid, and serum titers appear higher.7 The pathogenicity of 
BP180 autoantibodies was repeatedly confirmed in vitro and in vivo.7,25 In contrast, 
BP230 autoantibodies failed to spontaneously induce blisters in several animal 
studies.25,26 Several studies suggest that symptoms and binding capacity of BP230 
autoantibodies depend on coinciding intracellular epitope exposure, for instance by 
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ultraviolet irradiation, epithelial injury, or the transient presence of BP180 
autoantibodies.27,28 Recently, BP230 autoantibodies were found to bind in the skin 
and induce blisters in scurfy mice lacking regulatory T cells.29 Based on these 
findings we suggest that loss of regulatory T cell function, seen in the aging process, 
might also influence the pathogenic ability of circulating BP230 antibodies. Other 
studies linked epitope recognition to BP phenotype, with less inflammation when 
antibodies recognized the middomain of BP180, or the C-terminal domain of BP230 
in cases with BP230 antibodies only.24,30 Future studies are needed to illuminate the 
pathophysiology of nonbullous pemphigoid.  
 Interestingly, five patients with initial negative DIF results turned positive when 
DIF was repeated. This demonstrates that the used minimal diagnostic criteria truly 
support early diagnosis in pemphigoid.7 The changed DIF result coincided with 
blister development in one case, and in general no trend of altered antigen 
recognition, or relation with biopsy site was observed in these patients.  
 Our study provides data concerning treatment responses in nonbullous 
pemphigoid, with only limited data available on the treatment of localized cases. In 
generalized cases, the highest effectiveness was seen of methotrexate, followed by 
lesional clobetasol cream and whole body application of superpotent topical 
corticosteroids. Caution is advised for treatment with methotrexate in elderly 
patients, as many side effects were reported. Prednisolone often led to DC (58%), 
though all patients relapsed over time, suggesting it is useful for short-term disease 
control only. Lesional corticosteroids were ineffective in most cases, however, 
remission was still seen in 28%. Williams et al. showed non-inferiority of a treatment 
strategy starting doxycycline over prednisolone in BP.31,32 Our data showed that 
doxycycline was not effective in the majority (86%) of nonbullous pemphigoid 
patients. 
 Prognostic data of our study showed that 36% of the study population died after 
an average disease duration of 51.2 months. Compared to BP we found a lower 1-
year all-cause mortality rate in nonbullous pemphigoid, and similar to higher 2- and 
3-year all-cause mortality rates.5,6,33 Moreover, an overall SMR of 8.6 was found in 
nonbullous pemphigoid compared to reported SMR of 3.4, 3.6 and 6.6 in BP.5,6,33  
Our mortality data might be influenced by the low sample size, and limited follow-up 
data of cases that were censored in the Kaplan-Meier analysis. Furthermore, it can 
be hypothesized that the long delay in diagnosis, and therefore prolonged disease 
exposure without adequate treatment, might influence the prognosis. 
 A limitation of this study was the retrospective design. Consequently, disease 
severity measurements such as the BPDAI and autoantibody titers during follow-up 
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were not available. Moreover, the cause of death was unknown to the authors in 20 
of 25 deceased cases. A selection bias might affected epidemiology, treatment and 
prognostic results, since patients visiting an academic hospital are more likely to 
have severe complaints. Furthermore, our cohort misses patients residing in nursing 
homes who are not be able to visit a hospital, which could explaining the low co-
occurrence of neurodegenerative diseases in our cohort.3,4 Another limitation was 
the significant shorter follow-up in cases without blister formation, not allowing us to 
draw hard conclusions on the number of patients with late blister development.  
 This study brought insight in unrevealed disease aspects of nonbullous 
pemphigoid. Most important, pathologists and dermatologists should be aware that 
nonbullous pemphigoid cannot be excluded by histopathology and performance of 
DIF and IIF are required for diagnosis. Once the diagnosis is established, the best 
therapeutic effect was seen with methotrexate. The mortality rates in nonbullous 
pemphigoid are increased, indicating that a lack of blisters is not equivalent to 
having a better prognosis.  
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Table 1. Clinical characteristics of patients with nonbullous pemphigoid 
General characteristics 
Mean (SD; Range) 
or n (%) 
Mean age at diagnosis, years 76.1 (13.5; 39-101) 
Gender, n / n 29 M / 40 F 
Mean delay in diagnosis, months 28.9 (53.7; 0-385) 
Mean time of follow-up, months 21.9 (38.2; 0-218) 
Living in a nursing home, n (%) 7 (11.5) 
Location of symptoms  n (%)* 
Extremities 58 (92.1) 
Back 46 (79.3) 
Abdomen 29 (55.8) 
Scalp 18 (34.0) 
Hands/feet 16 (32.0) 
Neck 17 (31.5) 
Face 6 (12.0) 
Mucosa 0 (0.0) 
Findings during skin examination n (%)* 
Pruritus**  68 (98.5) 
      generalized pruritus  40 (58.0) 
      excoriations 52 (76.5) 
Localized disease** 6 (8.7) 
Xerosis cutis  8 (11.8) 
Papules/nodules 21 (30.9) 
Pruritus on primary nondiseased, noninflamed skin 15 (22.1) 
       3 sensu stricto 
 
Urticarial papules/plaques 8 (11.8) 
       1 with pustules 
 
Eczematous lesions 3 (4.4) 
Mixed skin findings 
 
       Urticarial papules/plaques + papules/nodules 10 (14.7) 
       Papules/nodules + eczematous lesions 1 (1.5) 
       Papules/nodules + erythematous macules  3 (4.4)  
Other 7 (10.3) 
       4 Erythematous plaques with squamous borders 
 
           2 pityriasis rubra pilaris-like 
 
       1 Suberythrodermia  
 
       1 Ulcerations 
 
       1 Localized livid, erythematous macules   
M, male; F, female; SD, standard deviation; R, range; ACE, angiotensin 
converting enzyme; DPP4, dipeptyl peptidase-4; * percentages were 
calculated after exclusion of cases of which data was unknown. ** Data 
extracted from anamnesis. ***Localized disease was defined as the 
presence of localized lesions involving one body site, conform the European 











Table 2. Diagnostic findings in nonbullous pemphigoid 
Histopathology (n=54) n (%)* 
Subepidermal split 1 (1.9) 
Spongiosis 22 (40.7) 
   without inflammatory cells 12 (22.2) 
   Eosinophilic spongiosis 3 (5.6) 
   Lymphocytic spongiosis 7 (13.0) 
Dermal lymphocytic infiltrate 53 (98.1) 
   located perivascular 49 (90.7) 
   presence of eosinophils 37 (68.5) 
DIF on a skin biopsy (n=68) n (%)* 
Positive DIF result 41 (60.3) 
   IgG 41 (60.3) 
   C3c 14 (20.6) 
   IgA 10 (14.7) 
   IgM 5 (7.4) 
   n-serrated pattern 19 of 41 (46.3) 
   indeterminable serration pattern  22 of 41 (53.7) 
Immunoserological findings (n=68) n (%)* 
Positive IIF result 47 (69.1) 
   IIF on MO, IgG 42 (61.8) 
   IIF on SSS, IgG  45 (66.2) 
   IIF on SSS, IgA  5 (7.4) 
Positive immunoblot results 37 (54.4) 
   BP180 9 (13.2) 
   BP230 28 (41.2) 
   BP230 doubtful 5 (7.4) 
Positive ELISA results 41 (60.3) 
   NC16A, n (%); mean titer u/mL 21 (30.9); 44.6 (SD 31.4; R 11-146) 
   BP230, n (%); mean titer u/mL 30 (46.9); 39.7 (SD 29.5; R 11-122) 
Eosinophilia in peripheral blood (n=57) 26 (44.8) 
   Mean titer, 10E9/L 1.02 (SD 0.61; R 0.4-2.4) 
DIF, direct immunofluorescence microscopy; IIF, indirect immunofluorescence 
microscopy; MO, monkey oesophagus;  SSS, salt split skin; LAD-1, linear IgA 
disease-1; ELISA, enzyme linked immunosorbent assay; NC16A, noncollagenous 
16a; SD, standard deviation; R, range.  
* Percentages were calculated after exclusion of cases of which data was unknown.  
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Table 3 
Table 3. Treatment response on first and second prescribed therapies in localized and generalized nonbullous pemphigoid.*  





time till DC,  
weeks 
Remission, 
either PR/CR PR 
time till PR, 
weeks CR 
time till CR, 
weeks relapses 
time till relapse, 
weeks 
Localizeda nonbullous pemphigoid (n=6) 
First (n=6) and second (n=2) therapies  n n n (%)** n (%)** mean (SD; R) n (%)** n (%)** mean (SD; R) n (%)** mean (SD; R) n (%)*** mean (SD; R) 
Lesional clobetasol cream 2 - 2 (100.0) - - - - - - - - - 
Doxycyline 2 - 1 (50.0) - - - - - 1 off (50.0) 5.0 - - 
whole body application of superpotent topical 
corticosteroids 1 1 - - - - - - - - - - 
Triamcinolon lesional 1 - - - - - - - 1 on (100.0) 5.0 - - 
Methotrexateb 1 - - 1 (100.0) 11.0 - - - - - - - 
Azathioprinec 1 - 1 (100.0) - - - - - - - - - 
Generalized nonbullous pemphigoid 
(n=61)   
First (n=61) and second (n=42) therapies  n n n (%)** n (%)** mean (SD; R) n (%)** n (%)** mean (SD; R) n (%)** mean (SD; R) n (%)*** mean (SD; R) 
Whole body application of superpotent topical 
corticosteroids 41 2 11 (28.2) 18 (46.2) 7.4 (8.3; 2-37) 10 (25.6) 
4 on (10.3); 
1 off (2.6) 17.8 (6.9; 9-28) 
1 on (2.6);   
4 off (10.3) 17.0 (11.1; 5-31) 12 (42.9) 
41.8 (80.3- 2-
275) 
Methotrexate (+ short-term prednisolone in 3) 15 1 3 (21.4) 5 (35.7) 11.8 (11.4; 3-29) 6 (42.9) 
4 on (28.6); 
1 off (7.1) 38.8 (31.5; 8-87) 1 on (7.1) 19.0 5 (45.5) 
94.6 (100.0; 8-
254) 
Prednisolone 13 1 3 (25.0) 7 (58.3) 4.3 (6.2; 1-18) 2 (16.7) 1 on (8.3) 17.0 1 on (8.3) 12.0 9 (100.0) 9.9 (5.3; 1-20) 
Lesional clobetasol cream 10 1 4 (44.4) 1 (11.1) 7.0 4 (44.4) 
2 on (22.2); 
1 off (11.1) 8.7 (8.0; 1-17) 1 off (11.1) 20.0 1 (20.0) 9.0 
Doxycyline (with or without nicotinamide) 5 - 5 (100.0) - - - - - - - - - 
Prednisolone + doxycycline 3 - 1 (33.3) 2 (66.7) 1.0 (0.0; 1-1) - - - - - 1 (50.0) 5.0 
Whole body application of superpotent topical 
corticosteroids  + doxycycline 2 - 1 (50.0) 1 (50.0) 4.0 - - - - - 1 (100.0) 3.0 
Prednisolone + azathioprine 3 - 1 (33.3) 2 (66.7) 3.0 (1.7; 2-5) - - - - - 1 (50.0) 14.0 
Dapson 3 1 1 (50.0) 1 (50.0) 8.0 - - - - - 1 (100.0) 1.0 
Other therapies 8 - 4 (50.0) 3 (37.5) 3.0 (1.7; 2-5) 1 (12.5) 1 off (12.5) 2.0 - - - - 
     3 Mometason (lesional, + tacrolimus in 2)      
     3 Triamcinolon (lesional) 
     1 Terbinafine (systemic) 
     1 Tacrolimus (lesional, topical) 
DC, disease control; PR, partial remission; CR, complete remission; on/off, on minimal/off therapy, as defined by international consensus1; SD, standard deviation; R, range.  
* Two cases did not receive therapy, one patient had minimal complaints and was lost to follow-up, and one first stopped suspected related medication and died shortly after.  
** Percentages were calculated without taking unknown responses into account. *** Percentages of patients relapsing were calculated over the number of cases that achieved DC, PR or CR.  
 a  Localized disease was defined as the presence of localized lesions involving one body site, conform the European consensus on the management of bullous pemphigoid 2015.15 
 b This patient had psoriasis, methotrexate was chosen as treatment for both skin diseases. c This patient used low dose azathioprine for Crohn’s disease, the dose was heightened when pemphigoid was diagnosed. 






























Table 4. Standardized mortality ratio's (SMR) in nonbullous pemphigoid  




mortality SMR 95% CI 
30-59 7 0 0.0018 0.0000 0.0  0.0 - 2.1 
60-69 10 1 0.0089 0.1000 11.2 9.1 - 13.7 
70-79 19 2 0.0243 0.1053 4.3 3.5 - 5.2 
80-89 26 5 0.0806 0.1923 2.4 2.1 - 2.7 
90 or older 7 0 0.2643 0.0000 0.0 0.0 - 0.1 
Total group (aged ≥30) 69 8 0.0134 0.1159 8.6 7.1 - 10.3 
SMR, standardized mortality ratio; CI, confidence interval. * Expected deaths in the Dutch population are based on population 
wide data of the year 2017. 
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FIGURE 1 
Figure 1. Nonbullous pemphigoid presenting with pruritus and various skin lesions. A. Papules 
and nodules. B. Pruritus on primary nondiseased, noninflamed skin with secondary 
excoriations. C. Urticarial papules and plaques. D. Eczematous lesions. 
 
